Point tools give you data.
BioAlma gives you decisions.

The Medical & Business intelligence platform for biotech — two functions, nine modules, one source of truth. Type a company name to see a live snapshot, free.

Nine modules. One login. One source of truth.

Medical Affairs and Business Development share one data model — a signal in one module updates the others, so every team works from the same continuously updated picture.

See it in a demo →
🤝

Medical Affairs CRM

KOL & HCP engagement, MSL activity, and interaction capture.

See it in a demo →
📈

Business Development CRM

Deal pipeline, partnering targets, and a diligence workspace.

See it in a demo →
🔬

Trial · PI · Site Tracker

Live status across investigators, sites, and enrollment.

See it in a demo →
⚔️

Competitive Intelligence

Competitor pipeline analysis and real-time updates.

See it in a demo →
🗺️

Provider & Market Intelligence

Maps, distributions, and segmentation analyses.

See it in a demo →
👥

Population Intelligence

Epidemiology and patient-population sizing.

See it in a demo →
🧬

Disease Intelligence

Prioritize targets across multi-indication portfolios.

See it in a demo →
📡

Scientific Platform

Omnichannel scientific communications management.

See it in a demo →
📅

Conference Planning & Tracker

Congress planning and session/content intelligence.

Intelligence briefs

Source-verified competitive intelligence across the gene, cell, and T-cell-engager landscape.

Browse all briefs →

The intelligence behind every MA & BD call

Synthesis is the product — BioAlma connects public, congress, client, and acquired data into one decision-ready view.

✨ Interactive

Synthesis is the product

BioAlma connects public, congress, client, and acquired data into one decision-ready view. Model competitive launches, market sizing, and risk on a visual canvas — every assumption structured, sourced, auditable, and ready for your board.

  • ✓ Public, congress, client, and acquired data in one view
  • ✓ Assumptions structured and traceable to sources
  • ✓ Shareable canvases for board and partner prep
  • ✓ What-if modeling with instant recalculation
Illustrative scenario
📊 QUESTION
GLP-1 obesity market by 2030?
💊 MARKET SIZE
Obesity: $130B TAM (2030)
Oral GLP-1: $48B segment
⚔️ COMPETITION
Wegovy, Zepbound + 12 in Ph3
Oral formulations: 5 programs
🟢 BEST CASE
Oral first-in-class
$8B peak sales
🟡 BASE CASE
3rd oral entrant
$3.2B peak sales
🔴 RISK
Muscle loss signal
Label restriction
📅 TIMELINE
Ph3 readout: Q4 2026
Filing: mid-2027
⚡ AI SYNTHESIS
Risk-adj. NPV: $4.7B (prob. weighted)
Based on 23 GLP-1 analogs • Updated live
🗺️ Provider & Market Intelligence

Your market, mapped

See where the market actually is. KOLs, treatment sites, and infusion centers in one geographic view — with patient distributions, referral patterns, and account segmentation layered on the same map your field teams plan against.

  • ✓ Infusion centers, treatment sites & KOLs on one US map
  • ✓ Patient & claims distributions by geography
  • ✓ Account segmentation and territory whitespace
  • ✓ The same provider intelligence powering the dashboard
Daniel Branco

Built by someone who's been in your shoes

BioAlma is the intelligence platform, and Daniel Branco is its human operator: a neurologist and venture builder who builds your intelligence boards and stays on the other end to think them through with you.

Meet the founder →

One platform for Medical Affairs and BD.

Nine modules on one source of truth — cloud or on-prem, with strict tenant isolation, so your protected data never powers a competitor's view.

Book a demo
BioAlma Family
SambaTrials ↗CoCreating.Bio ↗
© 2026 Uma Alma LLC · BioAlma is a brand of Uma Alma LLC · San Diego, California
BioAlma | Medical & Business Intelligence for Biotech